Biogennix Exhibits TrelCor Technology at North American Spine Society Meeting
IRVINE, Calif.--(BUSINESS WIRE)-- Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, exhibited its TrelCor™ technology at the North American Spine Society (NASS) annual meeting last week, including its newest product, Agilon™, which was recently cleared by the FDA for use in bone fusions.
Biogennix’s TrelCor technology is a proprietary material that has been engineered to provide the optimal chemistry and architecture for bone healing, and currently serves as the foundation for all of Biogennix’s bone fusion solutions.
TrelCor technology provides full interconnected porosity within naturally sourced calcium phosphate/calcium carbonate composite (CP/CC) granules. The interconnected pores average 500 microns (µm) in size, which mimics the natural blueprint of human cancellous bone. With TrelCor technology, all surfaces throughout the porosity are covered by a thin layer of calcium phosphate, the primary mineral content of bone. This thin layer and proprietary TrelCor formulation allow Biogennix bone grafting products to resorb at the proper rate.
Studies have shown that TrelCor technology allows Biogennix’s bone grafting material to become incorporated into a bone fusion, while gradually resorbing over a 6-12 month period – ideal for bone remodeling.
Among the products incorporating TrelCor technology, Agilon, which last month received 510(k) clearance and is now commercially available on the domestic market, is a bone grafting material that is fully biocompatible with human bone. Agilon was developed to address surgeon demand for a collagen-enhanced product, complementing the company’s existing flagship TrelCor products, Morpheus™ and osteoSPAN™. With Agilon, Biogennix has introduced the addition of a fibrous network of type-1 bovine collagen, for optimal material handling properties, among other potential benefits.
“We had a very good experience at NASS this year,” said Biogennix CEO Chris MacDuff. “Our proprietary TrelCor technology was well received by clinicians and distributors. At our booth on the exhibit floor, feedback on all products was extremely positive, especially for Agilon, which recently received 510(k) clearance by the FDA. When molding the product in their hands, the feedback we received across the board was on the superb handling when compared to other products, even after irrigation was introduced. Distributors also commented on the absorption capabilities of Agilon, especially after seeing how well it absorbed fluid.”
“In terms of how well-received all of our products were and the number of new contacts we made, this year’s NASS event was one of the best meetings Biogennix has attended to date,” said Scott Bauccio, Vice President of Sales and Business Development for Biogennix. “Our entire sales executive team was in Chicago for the meeting and we feel it was a very productive and positive week overall. We’re excited to continue carrying that enthusiasm forward as we continue to promote our TrelCor technology nationwide.”
Dr. Edwin Shors, President of Biogennix and one of the inventors of TrelCor technology, was on hand to speak about the chemistry and architecture the material provides, and to answer attendee questions about how TrelCor performs.
Biogennix designs, manufactures and distributes all of its products from its Irvine-based facilities.
Biogennix™ is a fully integrated osteobiologics company headquartered in Irvine which develops, manufactures, and distributes proprietary bone grafting products used in bone fusion procedures. Biogennix is committed to advancing technology behind natural bone grafting solutions, delivering outstanding quality with exceptional value, and customer-focused excellence. Learn more at biogennix.com.
Note to media: Photos of TrelCor are available upon request.
Media Contact: Paul Williams, 310-569-0023, email@example.com